|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...4950515253545556575859...156157» |
- Enrollment change, Trial termination: Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=2, Terminated, Sponsor: University of British Columbia
N=160 --> 2 | Recruiting --> Terminated; Some sites withdrew because no contract with insulin pump supplier
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Dec 5, 2015
P1, N=17, Active, not recruiting, Sponsor: UCB BIOSCIENCES, Inc.
N=160 --> 2 | Recruiting --> Terminated; Some sites withdrew because no contract with insulin pump supplier Recruiting --> Active, not recruiting
- ||||||| Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Dec 5, 2015
P3, N=201, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment status: RAPID-C OLE: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (clinicaltrials.gov) - Dec 5, 2015
P3, N=320, Enrolling by invitation, Sponsor: UCB Pharma SA
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- Enrollment open, Trial primary completion date: Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=40, Recruiting, Sponsor: University of British Columbia
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Jan 2016
- Enrollment open: PBR28 PET and Inflammatory Arthritis (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=12, Recruiting, Sponsor: University of Oxford
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Jan 2016 Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal, Trial primary completion date: Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Stirling
Not yet recruiting --> Recruiting N=12 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2012 --> Nov 2012
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New trial, Retrospective data: A Study on Rheumatoid Arthritis Patients Treated With Rituximab (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=81, Completed, Sponsor: Hoffmann-La Roche
- | Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Enrollment closed: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 5, 2015
P2, N=50, Active, not recruiting, Sponsor: Samsung Bioepis Co., Ltd.
N=12 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2012 --> Nov 2012 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Reducing Depressive Symptoms in Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=90, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=150 --> 90
- chloroquine phosphate / Generic mfg., prednisone / Generic mfg.
Trial primary completion date: Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial (clinicaltrials.gov) - Dec 5, 2015
P4, N=57, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
Active, not recruiting --> Completed | N=150 --> 90 Trial primary completion date: Dec 2014 --> Jun 2015
- ARG-301 / arGentis
Enrollment change: Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Dec 5, 2015
P1, N=22, Completed, Sponsor: VA Office of Research and Development
Trial primary completion date: Dec 2014 --> Jun 2015 N=32 --> 22
- | New P1 trial: A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy (clinicaltrials.gov) - Dec 5, 2015
P1, N=36, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Humalog pen (insulin lispro) / Eli Lilly
New P1 trial: A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps (clinicaltrials.gov) - Dec 5, 2015
P1, N=36, Not yet recruiting, Sponsor: Eli Lilly and Company
- Enrollment closed: CISAVID: Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome (clinicaltrials.gov) - Dec 5, 2015
P2, N=84, Active, not recruiting, Sponsor: University College Dublin
N=32 --> 22 Recruiting --> Active, not recruiting
- ||||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Trial completion: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 5, 2015
P3, N=584, Completed, Sponsor: Samsung Bioepis Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Adherence: Development of a Motivational Intervention to Improve Treatment Adherence in MS (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=80, Completed, Sponsor: University of Missouri, Kansas City
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| teriflunomide / Generic mfg.
Trial completion, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Dec 5, 2015
P4, N=1001, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Enrollment closed, Trial primary completion date: Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2015
P2, N=10, Active, not recruiting, Sponsor: Haukeland University Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date, MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Sep 2015 --> Apr 2016
- Biomarker, Enrollment closed: Neuroretinal Biomarkers in Neurodegenerative Diseases (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: University of Edinburgh
Trial primary completion date: Sep 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- Trial completion: Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=40, Completed, Sponsor: University of Missouri, Kansas City
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
Trial primary completion date: Immunogenicity of HPV Vaccine in Immunosuppressed Children (clinicaltrials.gov) - Dec 4, 2015
P3, N=55, Active, not recruiting, Sponsor: The University of New South Wales
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Mar 2016
- Trial primary completion date: Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: University of Aarhus
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Sep 2015 --> Feb 2016
- || vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2015
P2, N=168, Recruiting, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Sep 2015 --> Feb 2016 Trial primary completion date: May 2016 --> Nov 2015
- ||||| Enrollment closed, Trial primary completion date: Project JAY THA Registration Study (clinicaltrials.gov) - Dec 4, 2015
P3, N=96, Active, not recruiting, Sponsor: Smith & Nephew Orthopaedics (Beijing) Limited
Trial primary completion date: May 2016 --> Nov 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2016
- || Enrollment closed, Trial primary completion date: TC-A Registration Study (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=156, Active, not recruiting, Sponsor: Smith & Nephew Medical (Shanghai) Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Nov 2016
- Trial completion: A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=9, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Nov 2016 Active, not recruiting --> Completed
- |||| remtolumab (ABT-122) / AbbVie
Trial completion, P2 data: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Dec 4, 2015
P2, N=222, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ZB-168 / Zura Bio
Trial primary completion date: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2015
P1, N=35, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Mar 2016
- |||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) (clinicaltrials.gov) - Dec 4, 2015
P3, N=720, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2015 --> Mar 2016 Trial primary completion date: Sep 2016 --> Dec 2016
- Trial primary completion date, HEOR: Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=50, Recruiting, Sponsor: Philippe Klee
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change, Trial termination, Trial primary completion date: Evaluate Effects of Personalized Patient Counselling for Enbrel (clinicaltrials.gov) - Dec 4, 2015
P4, N=19, Terminated, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Dec 2016 N=300 --> 19 | Recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Oct 2015; Business Decision
- fingolimod / Generic mfg.
Enrollment closed, Trial primary completion date: Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=125, Active, not recruiting, Sponsor: University of Southern California
N=300 --> 19 | Recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Oct 2015; Business Decision Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- Trial primary completion date: Impact of Vasculitis on Employment and Income (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=400, Recruiting, Sponsor: University of South Florida
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Sep 2015 --> Jan 2016
- Trial completion, Enrollment change: GetFit: Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS (clinicaltrials.gov) - Dec 4, 2015
P2, N=32, Completed, Sponsor: University of Illinois at Urbana-Champaign
Trial primary completion date: Sep 2015 --> Jan 2016 Active, not recruiting --> Completed | N=80 --> 32
- Trial initiation date: Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes (clinicaltrials.gov) - Dec 3, 2015
P2, N=30, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Active, not recruiting --> Completed | N=80 --> 32 Initiation date: Oct 2015 --> Apr 2016
- Trial initiation date, Trial primary completion date: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes (clinicaltrials.gov) - Dec 3, 2015
P2, N=40, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Initiation date: Oct 2015 --> Apr 2016 Initiation date: Sep 2015 --> Mar 2016 | Trial primary completion date: Jul 2016 --> Oct 2016
- New P1/2 trial: Pre-POINT: Primary Intervention With Mucosal Insulin (clinicaltrials.gov) - Dec 3, 2015
P1/2, N=25, Completed, Sponsor: University of Colorado, Denver
- New trial: SONORE: Role of Ultrasound for Evaluating Rheumatoid Arthritis in Remission (clinicaltrials.gov) - Dec 3, 2015
P=N/A, N=110, Recruiting, Sponsor: University Hospital, Montpellier
- New trial: Edu4U: The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Dec 2, 2015
P=N/A, N=178, Enrolling by invitation, Sponsor: University of Louisville
- || Trial primary completion date: MD Logic Pump Advisor- Adults Study (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=135, Active, not recruiting, Sponsor: Rabin Medical Center
Initiation date: Sep 2015 --> Mar 2016 | Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- ARG-301 / arGentis
Trial completion: Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Nov 30, 2015
P1, N=32, Completed, Sponsor: VA Office of Research and Development
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- New trial: Evaluation of Automated Insulin Pump Settings Using the Advisor Pro (Previously Called) MD-Logic Pump Advisor-three Segments Study (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=34, Not yet recruiting, Sponsor: Rabin Medical Center
- ||| AZD9567 / AstraZeneca
Enrollment open: A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (clinicaltrials.gov) - Nov 30, 2015
P1, N=72, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Rabin Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Dec 2016
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) (clinicaltrials.gov) - Nov 30, 2015
P1, N=22, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Dec 2016 Recruiting --> Completed
- Trial primary completion date: Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial (clinicaltrials.gov) - Nov 28, 2015
P4, N=50, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Completed Trial primary completion date: Aug 2015 --> Jan 2016
- Enrollment closed, Trial primary completion date: The NOR-SWITCH Study (clinicaltrials.gov) - Nov 28, 2015
P4, N=500, Active, not recruiting, Sponsor: Diakonhjemmet Hospital
Trial primary completion date: Aug 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016
- Amevive (alefacept) / Astellas
Trial termination: T1DAL: Inducing Remission in Type 1 Diabetes With Alefacept (clinicaltrials.gov) - Nov 27, 2015
P2, N=49, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Jul 2016 Completed --> Terminated; Manufacturer discontinued production of Amevive